Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

Artur A. Serebrenik, Prokopios P. Argyris, Matthew C. Jarvis, William L. Brown, Martina Bazzaro, Rachel I. Vogel, Britt K. Erickson, Sun-Hee Lee, Krista M. Goergen, Matthew J. Maurer, Ethan P. Heinzen, Ann L. Oberg, Yajue Huang, Xiaonan Hou, S. John Weroha, Scott H. Kaufmann, Reuben S. Harris

Clin Cancer Res (2020) 26 (13): 3397–3407.

https://doi.org/10.1158/1078-0432.CCR-19-2786

Published: 01 July 2020

View articletitled, The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

Includes: Supplementary data

Journal Articles

Abstract A33: Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents

Arun Kanakkanthara, Catherine J. Huntoon, Xiaonan Hou, Minzhi Zhang, Ethan P Heinzen, Ann L. Oberg, John S. Weroha, Scott H. Kaufmann, Larry M. Karnitz

Clin Cancer Res (2020) 26 (13_Supplement): A33.

https://doi.org/10.1158/1557-3265.OVCA19-A33

Published: 01 July 2020

View articletitled, Abstract A33: Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents

Journal Articles

Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Clin Cancer Res (2020) 26 (13_Supplement): PR02.

https://doi.org/10.1158/1557-3265.OVCA19-PR02

Published: 01 July 2020

View articletitled, Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Journal Articles

Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Clin Cancer Res (2020) 26 (13_Supplement): IA02.

https://doi.org/10.1158/1557-3265.OVCA19-IA02

Published: 01 July 2020

View articletitled, Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Journal Articles

Abstract TMIM-069: PROSPECTIVE CLINICAL VALIDATION OF EX VIVO, PATIENT-SPECIFIC RESPONSE PREDICTION TO FIRST-LINE CHEMOTHERAPY

Stephen Shuford, Jeffrey Elder, Larry Puls, John Weroha, Xiaonan Hou, Valentina Zanfagnin, Alpa Nick, Michael P. Stany, Larry Maxwell, Thomas Conrads, Chris Corless, Anil K. Sood, Matthew Gevaert, Howland E. Crosswell, Teresa M. DesRochers

Clin Cancer Res (2019) 25 (22_Supplement): TMIM-069.

https://doi.org/10.1158/1557-3265.OVCASYMP18-TMIM-069

Published: 15 November 2019

View articletitled, Abstract TMIM-069: PROSPECTIVE CLINICAL VALIDATION OF EX VIVO, PATIENT-SPECIFIC RESPONSE PREDICTION TO FIRST-LINE CHEMOTHERAPY

Journal Articles

Abstract A17: Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma

HongZheng Res, XiaoNan Hou, Karlyn E. Pierson, Patric Eiken, Asha Nair, PingYang Yang, Joanne Eunhee Yi, Aaron S. Mansfield, Jin Jen

Clin Cancer Res (2018) 24 (17_Supplement): A17.

https://doi.org/10.1158/1557-3265.AACRIASLC18-A17

Published: 01 September 2018

View articletitled, Abstract A17: Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma

Journal Articles

Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors

Dana M. Walsh, Ismail Mert, Chen Jun, Xiaonan Hou, Saravut John Weroha, Marina Walther-Antonio

Clin Cancer Res (2018) 24 (15_Supplement): A70.

https://doi.org/10.1158/1557-3265.OVCA17-A70

Published: 01 August 2018

View articletitled, Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors

Journal Articles

Abstract A34: Targeting genes which are amplified in ovarian cancer

Faye R. Harris, Lin Yang, Xiaonan Hou, Konstantinos Leventakos, Saravut J. Weroha, George Vasmatzis, Irina V. Kovtun

Clin Cancer Res (2017) 23 (1_Supplement): A34.

https://doi.org/10.1158/1557-3265.PMCCAVULN16-A34

Published: 02 January 2017

View articletitled, Abstract A34: Targeting genes which are amplified in ovarian cancer

Journal Articles

Abstract B34: Integrated Approaches to Treating Lung Adenocarcinoma Resistant to Targeted Therapy

Jin Jen, Aaron Mansfield, Patrick W. Eiken, Shawn Stoddard, Karlyn Pierson, Xiaonan Hou, Hong Zheng Ren, Julian Molina, Joanne Yi, Ping Yang

Clin Cancer Res (2016) 22 (16_Supplement): B34.

https://doi.org/10.1158/1557-3265.PDX16-B34

Published: 15 August 2016

View articletitled, Abstract B34: Integrated Approaches to Treating Lung Adenocarcinoma Resistant to Targeted Therapy

Journal Articles

Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.

Caroline C. Nitschmann, Rachel M. Hurley, Marc A. Becker, Xiaonan Hou, Ute Hoch, Thomas C. Harding, Deborah H. Charych, Scott H. Kaufmann, Paul Haluska, Saravut J. Weroha

Clin Cancer Res (2016) 22 (2_Supplement): B50.

https://doi.org/10.1158/1557-3265.OVCA15-B50

Published: 15 January 2016

View articletitled, Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.

Journal Articles

Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Mariam Al Hilli, S. John Weroha, Marc Becker, Xiaonan Hou, Sean Harrington, Sarah McKinstrey, Kimberly Kalli, Karin Goodman, Keith Wilcoxen, Elizabeth Swisher, Scott Kaufmann, Paul Haluska

Clin Cancer Res (2013) 19 (19_Supplement): PR05.

https://doi.org/10.1158/1078-0432.OVCA13-PR05

Published: 13 May 2014

View articletitled, Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Journal Articles

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

Clin Cancer Res (2014) 20 (5): 1288–1297.

https://doi.org/10.1158/1078-0432.CCR-13-2611

Published: 02 March 2014

View articletitled, Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

Includes: Supplementary data

Journal Articles

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

Marc A. Becker, Xiaonan Hou, Sean C. Harrington, S. John Weroha, Sergio E. Gonzalez, Kristina A. Jacob, Joan M. Carboni, Marco M. Gottardis, Paul Haluska

Clin Cancer Res (2012) 18 (6): 1808–1817.

https://doi.org/10.1158/1078-0432.CCR-11-1806

Published: 14 March 2012

View articletitled, IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

Abstract A33: Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents

Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers

Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Abstract TMIM-069: PROSPECTIVE CLINICAL VALIDATION OF EX VIVO, PATIENT-SPECIFIC RESPONSE PREDICTION TO FIRST-LINE CHEMOTHERAPY

Abstract A17: Establishment of a unique patient-derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma

Abstract A70: Metformin alters the gut microbiota of ovarian cancer patients treated with carboplatin/paclitaxel chemotherapy and enhances sensitivity in resistant tumors

Abstract A34: Targeting genes which are amplified in ovarian cancer

Abstract B34: Integrated Approaches to Treating Lung Adenocarcinoma Resistant to Targeted Therapy

Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.

Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only